Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
Indications↗
Distinct diseases across all programs
Clinical Trials↗
All sponsored trials (all statuses)
Activity
Last 14 days
A Phase II Double-Blind Trial of Sulforaphane for Therapeutic Prevention of Melanoma in Patients With Multiple Atypical Nevi and a Prior History of Melanoma
COVID-19 Related Financial Hardship and Distress in Women Who Decline TMIST (EA1151) Participation
A Phase II Study of Daratumumab-Hyaluronidase for Chemotherapy-Relapsed/Refractory Minimal Residual Disease (MRD) in T Cell Acute Lymphoblastic Leukemia (T-ALL
A Randomized Phase II Trial Comparing Daratumumab-Bortezomib-Dexamethasone Versus Cyclophosphamide-Bortezomib-Dexamethasone in Newly Diagnosed Multiple Myeloma With Light Chain Cast Nephropathy (LCCN)
A Randomized Phase III Study to Evaluate Benefits of Autologous Stem Cell Transplant in Patients With Peripheral T Cell Lymphoma That Achieved a First Complete Remission (CR1) Following Induction Therapy (PTCL-STAT)
The ECOG-ACRIN SUPPORT Trial: Multilevel Intervention to Improve Diverse Enrollment in Cancer Clinical Trials
Details
Company Overview
—
Mkt Cap
—
Revenue
—
Cash
Regulatory
Neupogen — NEUPOGEN
Application BLA103353
Neupogen — NEUPOGEN
Application BLA103353
Neupogen — NEUPOGEN
Application BLA103353
Neupogen — NEUPOGEN
Application BLA103353
Neupogen — NEUPOGEN
Application BLA103353
Neupogen — NEUPOGEN
Application BLA103353
Neupogen — NEUPOGEN
Application BLA103353
Neupogen — NEUPOGEN
Application BLA103353
Neupogen — NEUPOGEN
Application BLA103353
Neupogen — NEUPOGEN
Application BLA103353
Neupogen — NEUPOGEN
Application BLA103353
Neupogen — NEUPOGEN
Application BLA103353
Neupogen — NEUPOGEN
Application BLA103353
Neupogen — NEUPOGEN
Application BLA103353
Neupogen — NEUPOGEN
Application BLA103353
Neupogen — NEUPOGEN
Application BLA103353
Neupogen — NEUPOGEN
Application BLA103353
Neupogen — NEUPOGEN
Application BLA103353
Neupogen — NEUPOGEN
Application BLA103353
Neupogen — NEUPOGEN
Application BLA103353
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)